Chemclin Diagnostics(SH:688468) Sou Hu Cai Jing·2025-08-07 11:45Core Viewpoint - Company Kemei Diagnostics has shown a significant increase in shareholder numbers and continues to innovate in the medical diagnostics field, despite a decline in revenue and net profit in the latest quarterly report [1]. Group 1: Company Performance - As of August 7, Kemei Diagnostics closed at 8.62 yuan, up 1.65%, with a rolling PE ratio of 33.50 times and a total market capitalization of 3.458 billion yuan [1]. - The latest quarterly report for Q1 2025 shows the company achieved operating revenue of 81.30 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]. Group 2: Industry Comparison - The average PE ratio for the medical device industry is 54.79 times, with a median of 37.86 times, placing Kemei Diagnostics at the 68th position within the industry [1]. - The company’s static PE ratio is 27.21 times, and its price-to-book ratio is 2.42 times [2]. Group 3: Shareholder Information - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]. Group 4: Innovation and Patents - During the reporting period, Kemei Diagnostics obtained 64 new domestic and international patents, including 33 domestic invention patents, 20 utility model patents, and 11 design patents, indicating strong innovation capabilities and technical reserves [1].